Myricetin as a promising inhibitor of platelet fibrinogen receptor in humans

Chang, Yi; Hsia, Chih-Wei; Huang, Wei-Chieh; Jayakumar, Thanasekaran; Hsia, Chih-Hsuan; Yen, Ting-Lin; Sheu, Joen-Rong; Hou, Shaw-Min

doi:10.1016/j.heliyon.2023.e20286

Cited by 3 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flavonoid aglycones exhibit antiplatelet effects, which are partly mediated by the inhibition of platelet activation induced by different agonists [41,78,82]. Consistent with previous studies [42,83], we confirmed that six flavonoid aglycones, including luteolin, myricetin, quercetin, eriodictyol, kaempferol, and apigenin significantly suppress thrombininduced platelet activation at a concentration of 100 µM. The observed inhibitory effects were comparable to the potent antiplatelet agent SNP, an NO donor, demonstrating the robust inhibitory potential of the tested substances.…”

Section: Discussionsupporting

confidence: 91%

“…Flavonoid aglycones exhibit antiplatelet effects, which are partly mediated by hibition of platelet activation induced by different agonists [41,78,82]. Consistent w vious studies [42,83], we confirmed that six flavonoid aglycones, including luteo…”

Section: Discussionsupporting

confidence: 85%

“…Noteworthy, the antiplatelet effect of aglycones was stronger in comparison with the effects exhibited by flavonoid glycosides [35]. In a recent study, myricetin demonstrated an antiplatelet effect over six times more robust than aspirin when assessed under similar conditions [42]. In mouse models, luteolin inhibited mesenteric artery thrombosis and collagen-adrenergic-induced pulmonary thrombosis without affecting coagulation, hemostasis, or platelet production [43].…”

Section: Introductionmentioning

confidence: 99%

“…Flavonoids isolated from Leuzea carthamoides, Premna foetida, and Ginkgo biloba have demonstrated strong antiplatelet effects [38][39][40]. Previous data indicated inhibitory effects of isolated flavonoid aglycones, including luteolin, myricetin, quercetin, eriodictyol, kaempferol, and apigenin, on platelet activation induced by various agonists [38,[41][42][43][44]. Noteworthy, the antiplatelet effect of aglycones was stronger in comparison with the effects exhibited by flavonoid glycosides [35].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Antiplatelet Effects of Flavonoid Aglycones Are Mediated by Activation of Cyclic Nucleotide-Dependent Protein Kinases

Balykina,

Naida,

Kirkgöz

et al. 2024

IJMS

View full text Add to dashboard Cite

Flavonoid aglycones are secondary plant metabolites that exhibit a broad spectrum of pharmacological activities, including anti-inflammatory, antioxidant, anticancer, and antiplatelet effects. However, the precise molecular mechanisms underlying their inhibitory effect on platelet activation remain poorly understood. In this study, we applied flow cytometry to analyze the effects of six flavonoid aglycones (luteolin, myricetin, quercetin, eriodictyol, kaempferol, and apigenin) on platelet activation, phosphatidylserine externalization, formation of reactive oxygen species, and intracellular esterase activity. We found that these compounds significantly inhibit thrombin-induced platelet activation and decrease formation of reactive oxygen species in activated platelets. The tested aglycones did not affect platelet viability, apoptosis induction, or procoagulant platelet formation. Notably, luteolin, myricetin, quercetin, and apigenin increased thrombin-induced thromboxane synthase activity, which was analyzed by a spectrofluorimetric method. Our results obtained from Western blot analysis and liquid chromatography–tandem mass spectrometry demonstrated that the antiplatelet properties of the studied phytochemicals are mediated by activation of cyclic nucleotide-dependent signaling pathways. Specifically, we established by using Förster resonance energy transfer that the molecular mechanisms are, at least partly, associated with the inhibition of phosphodiesterases 2 and/or 5. These findings underscore the therapeutic potential of flavonoid aglycones for clinical application as antiplatelet agents.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Antiplatelet Effects of Flavonoid Aglycones Are Mediated by Activation of Cyclic Nucleotide-Dependent Protein Kinases

Balykina,

Naida,

Kirkgöz

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…[ 83 ] Furthermore, myricetin demonstrated significant inhibition of the activation of the PI3K/AKT/GSK3β pathway in platelets stimulated by collagen at concentrations of 10, 20 μM, thereby serving as a potent antithrombotic agent. [ 84 ] These findings demonstrate the influence of the PI3K/AKT pathway on different therapeutic actions of myricetin. Further, Figure 2 illustrates the several mechanisms by which myricetin exerts its protective benefits through the PI3K/AKT pathway.…”

Section: Discussionmentioning

confidence: 81%

Unveiling myricetin's pharmacological potency: A comprehensive exploration of the molecular pathways with special focus on PI3K/AKT and Nrf2 signaling

Goyal,

Sikarwar,

Verma

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Myricetin can be found in the traditional Chinese medicinal plant, Myrica rubra. Myricetin is a flavonoid that is present in many vegetables, fruits, and plants and is considered to have strong antioxidant properties as well as a wide range of therapeutic applications. Growing interest has been piqued by its classification as a polyphenolic molecule because of its potential therapeutic benefits in both the prevention and management of numerous medical conditions. To clarify myricetin's traditional medical uses, modern research has investigated various pharmacological effects such as antioxidant, anticancer, anti‐inflammation, antiviral, antidiabetic, immunomodulation, and antineurodegenerative effects. Myricetin shows promise as a nutritional flavonol that could be beneficial in the prevention and mitigation of prevalent health conditions like diabetes, cognitive decline, and various types of cancer in humans. The findings included in this study indicate that myricetin has a great deal of promise for application in the formulation of medicinal products and nutritional supplements since it affects several enzyme activities and alters inflammatory markers. However, comprehensive preclinical studies and research studies are necessary to lay the groundwork for assessing myricetin's possible effectiveness in treating these long‐term ailments. This review summarizes both in vivo and in vitro studies investigating myricetin's possible interactions through the nuclear factor‐E2‐related factor 2 (Nrf2) as well as PI3K (phosphatidylinositol 3‐kinase)/AKT (protein kinase B) signaling pathways in an attempt to clarify the compound's possible clinical applicability across a range of disorders.

show abstract

Myricetin ameliorates cognitive impairment in 3×Tg Alzheimer’s disease mice by regulating oxidative stress and tau hyperphosphorylation

Wang,

Tang,

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Myricetin as a promising inhibitor of platelet fibrinogen receptor in humans

Cited by 3 publications

References 32 publications

Antiplatelet Effects of Flavonoid Aglycones Are Mediated by Activation of Cyclic Nucleotide-Dependent Protein Kinases

Antiplatelet Effects of Flavonoid Aglycones Are Mediated by Activation of Cyclic Nucleotide-Dependent Protein Kinases

Unveiling myricetin's pharmacological potency: A comprehensive exploration of the molecular pathways with special focus on PI3K/AKT and Nrf2 signaling

Myricetin ameliorates cognitive impairment in 3×Tg Alzheimer’s disease mice by regulating oxidative stress and tau hyperphosphorylation

Contact Info

Product

Resources

About